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pitalized children in Vietnam. RV, RSV, and HBoV may increase the
severity of ARIs in children.
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Background: Polio eradication is a global health priority and
Pakistan is among last three endemic countries. Supplementary
immunization activities (SIAs) with oral poliovirus vaccines are
usually separated by four week intervals; however, shorter inter-
vals have been used in security compromised areas and for rapid
outbreak response. We assessed immunogenicity of monovalent
type 1 oral poliovirus vaccines (mOPV1) administered at shorter
than usual intervals in a cohort of infants in Karachi, Pakistan.
Methods & Materials: A randomized controlled trial was con-
ducted to compare immunogenicity of two doses of mOPV1 given
at 7 or 14 day-intervals with standard 30 day interval. In addition,
bivalentOPV1&3 (bOPV)was administered at 30-day interval. Birth
trivalent OPV and two study OPV doses were administered and
blood samples obtained at birth, six weeks of age and one month
after the last OPV dose. Bloodwas tested for poliovirus neutralizing
antibodies.
Results: A total of 1009 newborns were enrolled, and 829
(82%) met eligibility criteria for randomization at 6 weeks; 554
(55%) were included in the per protocol analysis. Seroprevalence of
poliovirus neutralizing antibodies for poliovirus type 1 after three
doses of OPV was>95% for all arms. Among those who did not
seroconvert after birth dose, no signiﬁcant differences in serocon-
version to poliovirus type 1 after two study OPV doses were found
between study arms (75.0% [CI95%=65-83%] for mOPV1 given at
7 day interval, 75.0% [CI95%=65-83%] for mOPV1 at 14 day inter-
val, 78.1% [CI95%=69-86%] for mOPV1 at 30 day interval and 72.6%
[CI95%=63-81%] for bOPV at 30 day interval).
Conclusion: We found no differences in immunogenicity of
mOPV1 administered in shorter than standard intervals. These
results provide the scientiﬁc justiﬁcation for the expanded use of
the short-interval strategy to rapidly increase population immu-
nity, to control outbreaks, prevent importations, and in areas of
conﬂict where limited window of access can be created.
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Background: About 350 million people are chronically infected
with Hepatitis B Virus (HBV) and only a fraction will clear the
virus during their life-time. Current therapeutic options are unsat-
isfying, and life-long appliance of nucleoside-analogs can lead to
side effects and selection of resistant mutants. A new therapeu-
tic approach is to target viral mRNA transcripts for degradation
by the RNA induced silencing complex (RISC). This method holds
immense potency since theoretically an effective and long-term
suppression of viral transcripts can be achieved by a single dose of a
vector encoding for a short-hairpin RNA (shRNA). fter initial enthu-
siasm, reports of severe side effects in animal studies hampered
RNAi-based gene therapies entering the clinics. Several causative
mechanisms have been proposed: (1) Oversaturation of endoge-
nous factors, particular of Argonaute 2, leading to breakdown of
microRNA processing; (2) off-target effects caused by activity of
the passenger strand; and (3) artiﬁcial feeding of shRNAs into the
microRNA pathway downstream of drosha.
Methods & Materials: We designed a range of recombinant
Adeno-associated-virus (AAV) vectors expressing factors to specif-
ically address each of the proposedmechanisms: (1) Co-expression
of the shRNAwithArgonaute2; (2) co-expressionof the shRNAwith
a decoy to neutralize the passenger strand; and (3) expression of
the same siRNA-sequence from a microRNA backbone using a liver
speciﬁc polymerase III promoter. Vectors were injected i.v. in HBV-
transgenicmice and compared for efﬁcacy of HBV-suppression and
signs of toxicity.
Results: While the conventional approach of a polymerase III
promoter driven shRNA led to reductions of HBV-parameters of up
to 97% but was accompanied by elevated ALT levels and loss of
body-mass, co-expression of Argonaute 2 with the shRNA reduced
signs of toxicity with similar efﬁcacy of HBV-suppression. More
noteworthy, co-expression of the passenger strand decoy with the
shRNA not only abrogated toxicity, but also signiﬁcantly enhanced
HBV-suppression with long-term reductions of 99%. Liver speciﬁc
expression of the microRNA mimic showed ameliorated toxicity
but was less efﬁcient in suppressing HBV.
Conclusion: Understanding the mechanisms of RNAi-related
toxicity and the rational design of new expression vectors could
lead to the development of safe and efﬁcient RNAi-based thera-
peutics for chronic Hepatitis B.
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